A Clinical Trial of MK-3120 in People With Bladder Cancer (MK-3120-003)
Phase 1/2
45
about 3.2 years
18+
2 sites in CA, SC
What this study is about
This trial is testing a treatment called MK-3120 for people with bladder cancer. The goal is to learn about the safety and how well people tolerate this new medication after having their tumor removed from the bladder.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive MK-3120
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Who Discontinue Study Treatment Due to AEs, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
Secondary: Complete Response Rate (CRR)
Oncology